There are 2 new features, which make the PCDx test even better:

  1. As of now it is possible to perform an IHC (immunohistochemistry) for PD-L1 with the clone SP142. PD-L1 SP142 is the companion diagnostic for the immune-checkpoint-inhbitor Atezolizumab. Atezolizumab is applied in breast cancer, non-small cell lung cancer and bladder cancer.

  2. The presentation of the PCDx results report was revised and is more clear now. On the first page most relevant information regarding potential efficient therapies are displayed.